TY - JOUR
T1 - Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple Sclerosis
AU - Ruetsch-Chelli, Caroline
AU - Okuda, Darin T.
AU - Rocher, Fanny
AU - Tartare-Deckert, Sophie
AU - Deckert, Marcel
AU - Lebrun-Frenay, Christine
N1 - Funding Information:
We thank Mickael Ohanna and Marie Hirondelle for their help in the laboratory using the IncuCyte ZOOM live cell microscope. We have no source of financial support for this work. No funding or sponsorship was received for this study or publication of this article. Caroline Ruetsch-Chelli, Darin Okuda, Fanny Rocher, Christine Lebrun-Frenay, Sophie Tartare-Deckert and Marcel Deckert contributed to the conception and design of the study, data acquisition and data analysis, drafted and critically reviewed the manuscript. Caroline Ruetsch-Chelli, Darin Okuda, Christine Lebrun-Frenay contributed substantially to acquire data, and commented on, revised, and approved the final version to the data acquisition. Caroline Ruetsch-Chelli, Darin Okuda, Fanny Rocher, Christine Lebrun-Frenay, Sophie Tartare-Deckert and Marcel Deckert have nothing to declare. The experiments using melanoma cells derived from human tissue samples were conducted according to the principles of the Declaration of Helsinki. They had institutional approval (agreement no. 2137 from the French ministère de l’Enseignement supérieur et de la recherche). The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publisher Copyright:
© 2022, The Author(s).
PY - 2023/2
Y1 - 2023/2
N2 - Introduction: S1P1 receptor modulators (S1P1-RM) are oral disease-modifying therapies (DMTs) for multiple sclerosis (MS). Several authorities have raised doubts that S1P1-RM are responsible for an increased risk of melanoma in patients with MS. We studied the in vitro effects of S1P1-RM on different melanoma cell lines to compare the effect of available S1P1-RM on the proliferation of human melanoma cells. Methods: Four S1P1-RM were studied which are currently approved for managing MS, namely fingolimod (Gilenya®), siponimod (Mayzent®), ozanimod (Zeposia®), and ponesimod (Ponvory®). We tested these four drugs at different concentrations, including therapeutic doses (0.5, 1.6, 5.5, 18, and 60 µM), on human melanoma cell lines (501Mel cells, 1205LU cells, and M249R cells) to analyze in vitro cell proliferation monitored with the IncuCyte ZOOM live cell microscope (Essen Bioscience). Results: At therapeutic doses, median confluence increased overall for all lineages: + 122% for ozanimod (p < 0.001), + 71% for ponesimod (p < 0.001), + 67% for siponimod (NS), and + 41% for fingolimod (p = 0.094). Ozanimod- and ponesimod-treated cells increased confluency in 501Mel, 1205LU, and M249R cell lines (p < 0.001). Conclusion: These data suggest an increased proliferation of various melanoma cell lines with S1P1-RM treatments used at therapeutic concentrations for patients with MS and should raise the question of increased dermatologic surveillance.
AB - Introduction: S1P1 receptor modulators (S1P1-RM) are oral disease-modifying therapies (DMTs) for multiple sclerosis (MS). Several authorities have raised doubts that S1P1-RM are responsible for an increased risk of melanoma in patients with MS. We studied the in vitro effects of S1P1-RM on different melanoma cell lines to compare the effect of available S1P1-RM on the proliferation of human melanoma cells. Methods: Four S1P1-RM were studied which are currently approved for managing MS, namely fingolimod (Gilenya®), siponimod (Mayzent®), ozanimod (Zeposia®), and ponesimod (Ponvory®). We tested these four drugs at different concentrations, including therapeutic doses (0.5, 1.6, 5.5, 18, and 60 µM), on human melanoma cell lines (501Mel cells, 1205LU cells, and M249R cells) to analyze in vitro cell proliferation monitored with the IncuCyte ZOOM live cell microscope (Essen Bioscience). Results: At therapeutic doses, median confluence increased overall for all lineages: + 122% for ozanimod (p < 0.001), + 71% for ponesimod (p < 0.001), + 67% for siponimod (NS), and + 41% for fingolimod (p = 0.094). Ozanimod- and ponesimod-treated cells increased confluency in 501Mel, 1205LU, and M249R cell lines (p < 0.001). Conclusion: These data suggest an increased proliferation of various melanoma cell lines with S1P1-RM treatments used at therapeutic concentrations for patients with MS and should raise the question of increased dermatologic surveillance.
KW - Fingolimod
KW - Inflammation
KW - Melanoma cell lines
KW - Multiple sclerosis
KW - Ozanimod
KW - Ponesimod
KW - Siponimod
KW - Sphingosine-1 phosphate
UR - http://www.scopus.com/inward/record.url?scp=85144284618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144284618&partnerID=8YFLogxK
U2 - 10.1007/s40120-022-00429-6
DO - 10.1007/s40120-022-00429-6
M3 - Article
C2 - 36534273
AN - SCOPUS:85144284618
SN - 2193-8253
VL - 12
SP - 289
EP - 302
JO - Neurology and Therapy
JF - Neurology and Therapy
IS - 1
ER -